Stockwinners Market Radar for June 24, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:30 EDT Chemours resumes production at TiO2 site in Mexico - The Chemours Company announced that the Mexican government has lifted its prior water intake restrictions, enabling the Company to resume normal operations at its titanium dioxide manufacturing facility in Altamira, Mexico.

18:31 EDT Pool Corp. sinks 11% to $300.55 after cutting outlook

18:03 EDT Comstock Holding names Robert Demchak as new General Counsel - Comstock Holding announced the appointment of Robert Demchak to the Executive Leadership team as General Counsel and Corporate Secretary, effective June 24. Demchak brings over 25 years of experience as a real estate and capital markets attorney and as a REIT executive. His experience encompasses corporate governance, capital markets, regulatory compliance, and management of commercial real estate related transactions.

17:54 EDT Gossamer Bio CEO buys $250K in common stock - In a regulatory filing, Gossamer Bio disclosed that its CEO Faheem Hasnain bought 372K shares of common stock on June 21st in a total transaction size of $250K.

17:20 EDT Fresh2 Group plans to implement ADS ratio change - Fresh2 Group announced that it plans to change the ratio of its American depositary shares to its Class A ordinary shares from one ADS representing twenty Class A ordinary shares to one ADS representing two hundred Class A ordinary shares. The ADS ratio change is expected to become effective on or about July 10.

17:01 EDT Stran & Company receives Nasdaq notice over late 10-Q filing - Stran & Company announced that it received a written notification, dated June 21, 2024, from The Nasdaq Stock Market LLC, notifying the company that it is not in compliance with the periodic financial report filing requirement set forth in Nasdaq Listing Rule 5250(c)(1) for continued listing on The Nasdaq Capital Market tier of Nasdaq since the company has not yet filed its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024. The company has 60 calendar days, or until August 20, 2024, to submit a plan to Nasdaq to regain compliance, and, if Nasdaq accepts the Plan, Nasdaq may grant an exception of up to 180 calendar days from the Form 10-Q's due date, or until December 16, 2024, to regain compliance. If Nasdaq does not accept the Plan, the company will have the opportunity to appeal that decision to a Nasdaq Hearings Panel. As previously announced on May 13, 2024, the company was required to dismiss BF Borgers CPA PC as the company's independent registered public accounting firm. The Company was required to engage a new independent registered public accounting firm in order to complete and file the Form 10-Q. On June 20, 2024, the company announced that it had engaged a new independent registered public accounting firm, Marcum LLP.

16:48 EDT Ascendis Pharma presents data from Phase 2 ACcomplisH Trial of TransCon CNP - Ascendis Pharma announced the oral presentation of data from its Phase 2 ACcomplisH Trial of TransCon CNP in children aged 2 to 10 years old with achondroplasia by Ravi Savarirayan, M.D., Murdoch Children's Research Center, during ICCBH 2024, the International Conference on Children's Bone Health being held in Salzburg, Austria. The data showed that patients treated for one year at the pivotal 100undefined/kg/week dose demonstrated significant improvements in well-being and physical functioning compared to placebo. These improvements could not be explained by changes in linear growth only, supporting a potential additional direct treatment effect of TransCon CNP beyond linear growth.

16:38 EDT Advantage Solutions CEO buys $111.6K in common stock - In a regulatory filing, Advantage Solutions disclosed that its CEO David Peacock bought 40K shares of common stock on June 21st in a total transaction size of $111.6K. Shares of Advantage Solutions are up 2% afterhours at $2.93.

16:36 EDT Merck KGaA discontinues Phase III TrilynX study - Merck KGaA announced the discontinuation of the Phase III randomized TrilynX study evaluating xevinapant plus chemoradiotherapy in patients with unresected locally advanced squamous cell carcinoma of the head and neck. The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Top-line safety data were overall compatible with the chemo-radio sensitizing properties of xevinapant. The company will conduct an in-depth review of the data and will share the results in a peer-reviewed forum. LA SCCHN has proven to be a difficult-to-treat form of cancer. CRT has remained the standard of care for decades, despite multiple studies designed to improve outcomes with new treatment approaches, including multiple immunotherapy trials. "We sincerely thank the patients, caregivers and clinical investigators who participated in this trial," said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck KGaA, Darmstadt, Germany. "While we are disappointed by these results, we remain steadfast in our commitment to develop transformative medicines within our oncology portfolio for areas of high unmet need." Given the totality of the data, the company decided to also stop the Phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy) in patients who underwent resection of locally advanced head and neck cancer.

16:34 EDT J.M. Smucker CEO Smucker sells 10,000 common shares - In a regulatory filing, J.M. Smucker chairman, president, and CEO Mark Smucker disclosed the sale of 10,000 common shares of the company on June 21 at a price of $110.16 per share.

16:29 EDT Pool Corp. to resume trading at 4:30 pm ET - Pool Corp. shares are set to resume trading at 4:30 pm ET, with quotation scheduled to resume at 4:25 pm ET, according to Nasdaq.

16:27 EDT Mosaic: April-May potash sales revenue $371M vs. $672M last year - Previous second quarter 2024 guidance is reiterated. Potash sales volume and MOP prices at the mine are expected to be in the range 2.2-2.4M tonnes, and $210-$250 per tonne, respectively. Phosphates sales volumes and DAP prices at the plant are expected to be in the range of 1.6-1.8 million tonnes, and $530-$580 per tonne, respectively.

20:18 EDT Cohen & Steers says Raja Dakkuri to succeed Matthew Stadler as CFO - Cohen & Steers (CNS) announced that Raja Dakkuri has joined Cohen & Steers as Executive Vice President and CFO. Dakkuri succeeds Matthew Stadler, who previously notified Cohen & Steers on October 17, 2023 of his intention to retire during 2024 upon the appointment of his successor. As CFO, Dakkuri will lead the firm's financial operations, financial strategy and investor relations. He joins the firm's Executive Committee and reports to Joseph Harvey, CEO and President. Dakkuri joins Cohen & Steers from Valley National Bancorp and Bank (VLY), where he served as Chief Risk Officer.

16:11 EDT Nidar Infrastructure to go public via merger with Cartica Acquisition Corp - Nidar Infrastructure Limited and Cartica Acquisition Corp announced that they have entered into a definitive Agreement and Plan of Merger for a business combination. Nidar is India's leading data center provider for artificial intelligence and high-performance compute. Nidar provides advanced information technology infrastructure and solutions on an "as-a-Service" model to customers worldwide, including enterprises, governments, start-ups and small- and medium-sized enterprises, and hyperscalers. Nidar's offerings include colocation services, managed services and cloud services, and AI services. The pre-transaction equity value of Nidar implied by the Business Combination terms is approximately $2.75B.

16:08 EDT Orion Group awarded three contracts with total value of approximately $63M - Orion Group Holdings announced three contract awards, two in its Concrete segment and one in its Marine segment. Each of the three projects is scheduled to start in Q3 of 2024 and run for nine to twelve months.

20:08 EDT Illumina completes divestiture of Grail - Illumina (ILMN) announced the successful completion of the spin-off of Grail (GRAL). This milestone follows the company's previously announced plans to divest Grail, and Grail is now a public and independent company. Grail will begin regular way trading on Nasdaq on Tuesday, June 25 under the ticker symbol "GRAL." Illumina will continue to trade on Nasdaq under the ticker symbol "ILMN."

16:07 EDT Cleveland-Cliffs to host Senator Sherrod Brown, USW's McCall at Cleveland Works - Cleveland-Cliffs announced that Lourenco Goncalves, Chairman, President and Chief Executive Officer is hosting Senator Sherrod Brown of Ohio and leadership from the United Steelworkers, David McCall, USW International President and Donnie Blatt, Director of USW District 1, at its Cleveland Works plant in Ohio on Wednesday, June 26 for a press conference. Senator Brown's visit follows the recent bipartisan legislation introduced to stop the dramatic increase in Mexican steel imports. The Stop Mexico's Steel Surge Act reinstates the 232 tariffs on Mexican steel imports at 25 percent, for no less than a year, and gives the President of the United States the authority to impose additional quotas and tariff rate quotas on specific products if necessary. Senator Brown has led efforts pushing the current administration to take aggressive action to enforce the agreement to level the playing field for American manufacturers and workers in the steel industry, the company said. During the visit, Senator Brown will meet with Cleveland-Cliffs' CEO Lourenco Goncalves and USW International President David McCall, as well as with local union leaders and employees regarding this important trade enforcement matter.

16:06 EDT Rigel Pharmaceuticals completes transfer of GAVRETO NDA - Rigel Pharmaceuticals announced the completion of the transfer to Rigel of the New Drug Application for GAVRETO for the treatment of adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by a U.S. FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. GAVRETO will be commercially available from Rigel in the U.S. by prescription beginning June 27, 2024.

16:04 EDT Iron Mountain CHRO Baker-Greene sells 6,200 common shares - In a regulatory filing, Iron Mountain executive VP and chief HR officer Edward Baker-Greene disclosed the sale of 6,200 common shares of the company on June 20 at a price of $88.35 per share.

16:01 EDT Hyzon Motors announces realigning of strategic priorities - Hyzon announced that after a comprehensive review of Hyzon's business operations, Hyzon has started realigning its strategic priorities along several lines to focus on the company's core North American markets and the refuse industry. In addition to the company's previously disclosed efforts to secure capital, the company announced that it has retained PJT Partners as its financial advisor to lead the ongoing capital raise efforts including via capital markets transactions, and to explore a full range of strategic options for the company, which could potentially include a sale of the company and/or a divestiture of its Europe and Australia/New Zealand businesses and subsidiaries, amongst other alternatives. As the company explores such strategic alternatives, it will continue to focus on cost reduction efforts and managing liquidity, including a reduction in work force or other strategic transactions and/or measures. The realignment process will allow Hyzon to focus its financial resources and investments, better position its first-to-market, single stack 200kW, fuel cell technology in its zero emissions North American Class 8 and refuse truck FCEV platforms as it prepares to launch its significant large fleet trial programs on both platforms in the U.S. and Canada this summer.

18:50 EDT Bitfarms says Riot has declined to engage 'constructively' - Bitfarms (BITF) confirmed that it has received a shareholder meeting requisition from Riot Platforms (RIOT). The shareholder meeting is being requisitioned to gain control of the company's Board of Directors. Bitfarms issued the following statement: "The Bitfarms Board of Directors and management team are committed to acting in the best interests of the Company and all of its shareholders. In that regard, the Board established a Special Committee of independent directors to conduct a strategic alternatives review process to thoroughly evaluate all opportunities to maximize shareholder value. The Special Committee determined that Riot's April 22, 2024 proposal of $2.30 per share (which represents a 22% discount to Bitfarms closing price as of June 21, 2024) significantly undervalued the Company and offered to enter into a confidentiality and standstill agreement with Riot and provide additional information about the Company so that Riot could improve its proposal. Since that time, the Special Committee has repeatedly invited Riot to participate in the process, even executing the confidentiality and standstill agreement proposed by Riot. The Special Committee is disappointed that Riot declined to engage constructively and participate in the process, and instead has continued to take steps to attempt to undermine the integrity of the process and harm the interests of other Bitfarms shareholders. The Board and Special Committee remain committed to achieving the best outcome for all Bitfarms shareholders." The company remains committed to constructive engagement with all shareholders and will review the requisition and provide an update in due course. Bitfarms shareholders are not required to take action at this time.

13:32 EDT Novo Nordisk presents full results from FLOW trial of Ozempic - Novo Nordisk presented the full results from FLOW, its phase 3b kidney outcomes trial investigating the effects of once-weekly injectable semaglutide 1 mg in adults with type 2 diabetes and chronic kidney disease, or CKD, at the 84th Annual Scientific Sessions of the American Diabetes Association, or ADA. The double-blind, randomized, placebo-controlled trial, which enrolled 3,533 people with type 2 diabetes and CKD, achieved its primary endpoint, with semaglutide 1 mg demonstrating a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. The primary outcome was major kidney disease events, a composite of onset of kidney failure, a sustained 50% or greater reduction in eGFR from baseline, or death from kidney-related or cardiovascular causes. "Treating serious comorbidities like chronic kidney disease is critical to improving treatment outcomes for people with type 2 diabetes. The results from the FLOW trial represent important data, as we look to better understand what GLP-1 treatment options could mean for this patient population. Leveraging our deep expertise in cardiometabolic science, we are proud to continue building strong clinical evidence on the strength and versatility of semaglutide to deliver results for people living with serious chronic diseases," said Anna Windle, PhD, senior vice president clinical development, Medical & Regulatory Affairs at Novo Nordisk.

13:19 EDT Digital Health Acquisition Corp trading resumes

13:08 EDT Nvidia Head of IR says leaving for 'startup CFO opportunity' - Simona Jankowski, Vice President, Head of Investor Relations & Strategic Finance at NVIDIA, stated in a LinkedIn post: "After seven amazing years, I have decided to leave NVIDIA for a startup CFO opportunity (more on that in a future post). It was not an easy decision. NVIDIA has been close to my heart for over two decades. As a newly minted equity research analyst at Goldman Sachs in 2001, my first assignment was building the NVDA financial model, and I met Jensen Huang as part of our initiation of coverage. I loved following the stock throughout the 2000s - cool product launches, rapid technology advances, supply chain trips to Taiwan, Q&As with Jensen, the birth of CUDA - these were fertile ground for many tech deep dives and (mostly good) stock calls. It helped me make my name as an analyst and I learned a lot." Reference Link

12:26 EDT Norfolk Southern says addresses FRA's safety culture assessment recommendations - Norfolk Southern Corporation said it has implemented measures to address the Federal Railroad Administration's recommendations from its 2023 Safety Culture Assessment. The Assessment, issued in August 2023, made recommendations in the areas of communications, training, trust, and going above and beyond regulatory minimums. Norfolk Southern, working with its independent safety consultant AtkinsRealis US Nuclear, developed action items in response to these recommendations. The company has successfully launched initiatives to implement all items and will monitor these actions to ensure their effectiveness. "We appreciate the strong partnership with FRA on advancing safety and are grateful for its thorough assessment of our culture and their thoughtful recommendations, all of which serve as building blocks to our goal of becoming the gold standard for safety in the industry," said Alan H. Shaw, president and CEO of Norfolk Southern. Norfolk Southern and FRA worked closely together throughout the implementation of the responsive action items. The company provided frequent updates to FRA on its progress, which included briefings by Shaw to FRA Administrator Amit Bose and his senior leadership team.

12:04 EDT ResMed falls -11.3% - ResMed is down -11.3%, or -$23.33 to $182.50.

12:02 EDT Redwire rises 15.3% - Redwire is up 15.3%, or 89c to $6.72.

12:00 EDT RXO Inc. rises 23.2% - RXO Inc. is up 23.2%, or $4.69 to $24.90.

11:10 EDT Lead Real Estate board approves special cash dividend - Lead Real Estate's Board of Directors approved a special cash dividend, payable on or about September 30, 2024, to all shareholders of record as of June 30, 2024 with an American depositary receipt record date of June 28, 2024. The dividend will be subject to shareholder approval at the Company's annual general meeting to be held in September 2024.

10:33 EDT Cadeler reports contract for installation of 72 15MW wind turbines at Inch Cape - In a regulatory filing earlier, Cadeler A/S announced the signing of a firm contract with Inch Cape Offshore Limited for the installation of 72 Vestas 15MW offshore wind turbines at Inch Cape Offshore Wind Farm. "The contract value is projected to fall within the range of EUR 114 - 130 million, with installation due to commence in the fourth quarter of 2026. This project illustrates Cadeler's commitment to expanding its partner portfolio, while strengthening and diversifying its contract backlog. Located 15 kilometres off the East Coast of Scotland in the North Sea, Inch Cape Offshore Wind Farm will generate enough energy to power the equivalent of approximately 1.6 million UK households. For the successful execution of this project, Cadeler will utilize one of its two state-of-the-art newbuild M-class installation vessels. The overall duration of the project is estimated to be around 249 days," the company stated. Mikkel Gleerup, CEO of Cadeler, said: "This contract once again illustrates the increasing demand for our new build state-of-the-art vessels and our commitment to expanding our partner portfolio, while strengthening our overall contract backlog. With the recent renewal and continuing expansion of our fleet of jack-up offshore wind installation vessels - the industry's largest - Cadeler is ready to meet the fast-growing and dynamic market demand." Reference Link

10:06 EDT Stratasys, AM Craft partner to drive growth in 3D part manufacturing - Stratasys and AM Craft are partnering to align the two companies' efforts to grow the demand for flight-certified 3D printed parts in the aviation industry. The companies signed a definitive commercial collaboration agreement, along with Stratasys' strategic investment in AM Craft. Holding an EASA Part 21G Production Organization Approval, AM Craft solves a key barrier to broader adoption of 3D printed parts in the aviation industry by delivering airworthiness certified parts to airlines, MROs, and OEMs. Additive manufacturing has strong appeal as a supply chain solution in these markets due to the long sustainment life of aircraft and the resulting challenges in forecasting and stocking replacement parts.To facilitate the partnership with Stratasys, Stratasys SVP Jeff Hemenway is joining the AM Craft board of directors. AM Craft currently produces aviation components in Europe and has demonstrated the ability to extend their Production Organization Approval to Paradigm 3D, a partner company in Dubai, UAE. Stratasys currently engages in certified aviation parts manufacturing through subsidiary Additive Flight Solutions in Singapore. In structuring this partnership, AM Craft will own and operate AFS, further extending AM Craft's production network to Southeast Asia, and add a Hamburg facility later this year. The combined network operates 13 printers under EASA 21G approval, which have produced more than 28,000 flight parts to date. A future step within the partnership will be to evaluate collaboration with US-based Stratasys Direct Manufacturing, and their substantial install base of similar equipment.

10:04 EDT Microvast, Evoy forge partnership for boat electrification - Microvast Holdings announced a strategic partnership with Evoy, a Norwegian company specializing in high-output electric motor systems for boats. The collaboration with Evoy is Microvast's debut in the electric boat segment and marks an expansion of Evoy's battery options for diverse market applications. Evoy will be integrating Microvast MV-I high-power battery packs into their leisure boat product line. The MV-I battery pack offers a range of environmental and technical benefits, such as fast responsive torque for quick acceleration.

10:03 EDT Inspire Medical falls -13.2% - Inspire Medical is down -13.2%, or -$21.45 to $141.01.

10:02 EDT Redwire rises 6.5% - Redwire is up 6.5%, or 38c to $6.21.

10:00 EDT RXO Inc. rises 14.3% - RXO Inc. is up 14.3%, or $2.88 to $23.09.

09:52 EDT Mytheresa falls -6.7% - Mytheresa is down -6.7%, or -33c to $4.60.

09:51 EDT ResMed falls -7.5% - ResMed is down -7.5%, or -$15.54 to $190.29.

09:50 EDT Inspire Medical falls -10.8% - Inspire Medical is down -10.8%, or -$17.49 to $144.97.

09:48 EDT Prudential plc rises 6.9% - Prudential plc is up 6.9%, or $1.25 to $19.26.

09:45 EDT Lead Real Estate Co Ltd (ADR) trading halted, volatility trading pause

09:41 EDT SWVL Holdings Corp trading halted, volatility trading pause

09:33 EDT TMT Acquisition merger partner eLong Power receives RMB480M purchase order - The merger partner of TMT Acquisition Corp, eLong Power Holding, announced that its wholly-owned subsidiary has signed a supply contract for energy storage systems valued at RMB480M, approximately $66M. The execution of this supply contract follows a strategic partnership agreement signed last year with a major general contractor in the Chinese energy construction industry. The contract is for a 600MWh lithium battery storage system to be installed for a municipal project in Shandong province, China, with delivery expected by October 31, 2024. The contract contains provisions for an advance payment of 30% of the total contract price 3 months prior to shipment, an additional 60% within 7 business days after product delivery and installation with the 10% balance subject to product quality assurances for a year thereafter. Additionally, the contract contains penalties for late delivery by eLong Power and late payments by the buyer, as well as protections for eLong Power in the case of unilateral termination by the buyer.

09:27 EDT Carbon Revolution secures $25M financing agreement - Carbon Revolution has reached an agreement with Orion Infrastructure Capital for the early release of a further $25 million in five tranches, each equal to $5 million, subject to satisfying certain reserve release conditions. In connection with the release of each of the five tranches of $5 million from escrow, the Company will issue to OIC a warrant to purchase a number of shares equal to 2.5% of the Company's shares outstanding. The incremental $25 million of capital to be funded from OIC is intended to fund the Company as it works to satisfy the growing demand from Carbon Revolution's OEM customers. The Company is making substantial investments in capacity and throughput and has been producing wheels at record rates.

09:25 EDT Pineapple Energy's SUNAation enters installation agreement - SUNation Energy announced that they will be installing a custom roof-mounted solar system on the National Training Center of the Guide Dog Foundation and America's VetDogs, sister national nonprofit organizations, based in Smithtown, New York. The nonprofits breed, raise, train, and place highly trained assistance dogs with individuals with disabilities, free of charge. The solar installation is slated to reduce the nonprofits' operating expenses, allowing more of their resources to go directly towards the services they provide. Guide Dog Foundation and America's VetDogs both receive the highest ratings for financial stewardship and transparency from the leading charitable watchdog organizations. The nonprofits rely on contributions from generous individuals, corporations, service clubs, and foundations to fund its programs and services. The project's costs were significantly offset by a donation from Contract Pharmacal, a global manufacturer of pharmaceutical products, also based on Long Island. In addition to the support from Contract Pharmacal, the project is benefitting from federal Investment Recovery Act funding. Work is expected to begin in July 2024.

09:24 EDT Sellas Life Sciences granted Rare Pediatric Disease Designation for SLS009 - SELLAS Life Sciences Group announced that the U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to SLS009, a highly selective CDK9 inhibitor, for the treatment of pediatric acute lymphoblastic leukemia. Childhood ALL is a life-threatening disease with a high unmet medical need. Despite significant advances in the treatment of pediatric ALL, relapse continues to be the most common cause of treatment failure. There are patient subpopulations with high-risk and very high-risk features in need of less toxic therapies that would ultimately extend their long-term event-free survival which remains around 50% for very high-risk groups. In clinical trials, SLS009 has demonstrated a very favorable safety profile with complete absence, to date, of any non-hematologic clinical higher-grade toxicities.

09:21 EDT Wallbridge Mining engages ICP Securities for automated market making services - Wallbridge Mining Company announced an agreement to engage the services of ICP Securities to provide automated market making services, including the use of its proprietary algorithm, ICP Premium, in compliance with the policies and guidelines of the TSX Exchange and other applicable legislation. Under terms of the Agreement, ICP will receive a monthly fee, with there being no performance-based factors. No stock options or other forms of equity-based compensation will be granted in connection with the Agreement. ICP and its clients may choose to acquire an interest in the securities of the Company in the future. ICP is an arm's length party to the Company. ICP's market making activity will be primarily aimed at correcting temporary imbalances in the supply and demand of the Company's shares. ICP will be responsible for the costs it incurs in buying and selling the Company's shares, and no third party will be providing funds or securities for the market making activities.

09:20 EDT Broadcom previews highlights of VMware Explore 2024 - Broadcom previewed highlights of VMware Explore 2024, the industry's essential cloud event. VMware Explore 2024 will kick-off in Las Vegas on August 26-29, 2024 at The Venetian Convention and Expo Center. That event will be followed by VMware Explore 2024 in Barcelona, Spain on November 4-7, 2024 at the Fira Gran Via. VMware Explore Las Vegas will include a general session featuring Broadcom leaders, VMware experts, and customers showcasing advancements in private cloud, generative AI, app delivery, and the edge. The event will also offer hundreds of user-driven panels, certification training, and labs on industry and technology topics. Content will cover advanced cloud solutions for infrastructure modernization, accelerating app development, comprehensive networking and security, and other innovation topics such as private AI. For those that are unable to attend the Las Vegas conference in-person, Broadcom will live stream the general session on August 27, 2024.

09:19 EDT Solitario COO Walter Hunt to retire - Walter Hunt, Solitario's COO, will be retiring from Solitario at the end of June. Walt has been with the Company for over 30 years directing various exploration, development and permitting activities for Solitario. Solitario recently expanded its Golden Crest project management team with the addition of Sandor Ringhoffer. Sandor comes to Solitario with over 36 years in the gold exploration arena, 19 years of which were spent with Agnico Eagle. Most recently, Sandor was project manager for Agnico Eagle's Gilt Edge gold mine re-evaluation project in the Black Hills.

09:17 EDT Solitario receives final USFS approval on plan for Golden Crest Gold project - Solitario Resources announced that its final revised Plan of Operations for its Golden Crest project has been signed by US Forest Service. Additionally, the South Dakota Board of Minerals has accepted Solitario's reclamation bond paving the way for exploration drilling to begin. We are now in the process of mobilizing drilling equipment and organizing support equipment necessary for our drilling operations. Several drill targets are planned to be tested, including Downpour, Whirlwind, Matchstick and Mirage. None of these high-quality gold targets have ever been drilled before.

09:14 EDT Verizon Frontline showcases advanced communications solutions at TechNet Cyber - Verizon Frontline will demonstrate a number of innovative solutions designed to deliver mission-critical communications capabilities to public safety, government and military agencies during AFCEA's annual TechNet Cyber event. Taking place June 25-27 at the Baltimore Convention Center, AFCEA TechNet Cyber brings together leaders from all areas of government to discuss the policy, strategic architecture, operations and command & control - along with the joint capabilities-needed to meet global security challenges and successfully operate in a digital environment. During the TechNet Cyber, Verizon Frontline will showcase its Tactical Humanitarian Operations Response platform, an innovative deployable asset built to provide public sector partners - including the Department of Defense and first responders - with the full range of Verizon Frontline technology. With capabilities ranging from mobile, private 5G ultra wideband, to satellite, to commercial and onboard drone options, to the ability to be operated remotely from a tablet, THOR could be considered the multi-tool of Verizon Frontline assets.

09:12 EDT Shineco enters into securities purchase agreement for gross proceeds of $7M - Shineco, entered into a Securities Purchase Agreement with certain non-U.S. investors. Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock to the Purchasers in a private placement financing transaction at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000, before the deduction of customary expenses. The Purchasers are a former related party of the Company, who agreed to purchase 1,000,000 shares of common stock, a management member of the Company, who agreed to purchase 200,000 shares of common stock, and an individual investor who agreed to purchase 200,000 shares of common stock. The Offering is expected to close, and the Shares are expected to be issued, on or about July 31, 2024. The Company plans to use the proceeds from this offering for working capital and general corporate purposes, further bolstering the execution of its strategic initiatives.

09:10 EDT Sitka announces acquisition of Victoria Gold's Clear Creek Property - Sitka Gold announces that the Company has executed a definitive asset purchase agreement with Victoria Gold Corp. dated June 24, 2024 in connection with the acquisition of a 100% interest in the Clear Creek property, located adjacent to the Company's RC Gold Project. The Clear Creek Property claims adjoin Sitka Gold's road accessible RC Gold Project located approximately 100 kilometres east of Dawson City, Yukon and cover the southern portion of the Clear Creek Intrusive Complex. The Property encompasses several regions of intrusion-related gold mineralization that have undergone various levels of exploration, including historical reverse circulation and diamond drilling. Pursuant to the Purchase Agreement, the Company issued to Vendor an aggregate of 21,843,401 common shares in the capital of the Company as an initial payment, representing 8% of the issued and outstanding shares of Sitka after giving effect to the issuance of the Shares. In order to complete the Acquisition, the Company is required to make the following additional payments: $2,000,000 on or before August 30, 2025; $3,000,000 on or before June 24, 2026; and $6,000,000 on or before June 24, 2027. During the term of the Purchase Agreement while the Deferred Payments are pending, Sitka will act as operator of the Clear Creek Property and have control over its work programme. The Company may, in its sole discretion, satisfy any Deferred Payment in cash or through the issuance of such number of Shares as is equal to the amount of the applicable Deferred Payment based on the volume weighted average price of the Shares on the TSX Venture Exchange for the 20 consecutive trading days immediately prior to the due date of the applicable Deferred Payment, provided however that in the event that any such Share issuance would result in the Vendor holding greater than 19.9% of the issued and outstanding Shares of the Company, the Company must first obtain: the written consent of the Vendor to receive such Shares; and approval of the shareholders of the Company in accordance with Exchange policies. As additional consideration, upon completion of the Acquisition, the Company will grant to the Vendor a 5.0% net smelter return royalty on the Property. The Company shall have the right at any time following the grant of the NSR Royalty to purchase from the Vendor 60% of the NSR Royalty by way of a one-time cash payment of $10,000,000. In the event that the Company publicly delineates proven and probable mineral reserves of 2,000,000 ounces or more of gold or gold equivalent on the Property, then the Company shall make an additional payment of $10,000,000 in cash to the Vendor within 60 business days of such public delineation. In the event that the Company has not made such public delineation before the fifth anniversary of the Purchase Agreement, then the Vendor shall have the right to cause an evaluation by an independent qualified personto be conducted as to the extent of the mineral resources on the Property, and, in the event such qualified person determines the existence of measured and/or indicated resources of 2,000,000 ounces or more of gold or gold equivalent on the Property, then the Company shall make the $10,000,000 cash payment to the Vendor within 60 business days. In connection with the Purchase Agreement, the parties have entered into an investor rights agreement pursuant to which, among other things: at any time in which the Vendor shall have beneficial ownership of at least 15% of the issued and outstanding Shares of the Company, the Vendor shall have the right to nominate one director to the board of directors of the Company; and the Vendor has been granted certain customary anti-dilution and registration rights.

09:08 EDT NN, Inc. appoints Chris Bohnert as Chief Financial Officer - NN announced the appointment of Chris Bohnert as Chief Financial Officer, effective June 25 Bohnert brings over 30 years of global manufacturing leadership experience as an accomplished CFO with significant experience in successful business transitions and deep accounting expertise. Bohnert will report directly to NN's Chief Executive Officer, Harold Bevis. Bohnert succeeds Mike Felcher, who is departing the company to pursue other opportunities. Felcher will stay on as a consultant to assist with the transition. "Chris's deep experience in manufacturing company turnarounds, IT, investor relations, and banking will make an immediate impact," said Harold Bevis, President and CEO of NN, Inc. "Chris and I have worked together before and now is the right time to make this change. We are going to both pick up the pace and broaden our objectives. Chris is operationally savvy, proactive and has a track record of delivering results. This will be an accelerator for NN's transformation."

13:06 EDT MoneyLion appoints Kaplan as Chief Revenue Officer - MoneyLion (ML) announced the appointment of Jon Kaplan as the company's first Chief Revenue Officer, CRO. Kaplan brings a wealth of experience and a proven track record of driving growth and innovation at iconic technology companies, including Pinterest (PINS).

09:06 EDT Velo3D announces Mears Machine has acquired a Sapphire XC printer - Velo3D announced Mears Machine Corporation, a leader in precision machining solutions, has acquired a Sapphire XC printer to bolster its additive manufacturing capabilities. This strategic investment underscores Mears Machine's commitment to adopting advanced manufacturing technologies and follows the previous purchase of two Velo3D Sapphire XCs announced earlier this year. "As precision machine shops look to adopt advanced manufacturing technologies, like 3D printing, we are pleased to support their mission to modernize and better serve their customers," said Brad Kreger, CEO of Velo3D. "We are thrilled to partner with Mears Machine as they integrate a third Sapphire XC printer into their operations. Our technology is designed to empower manufacturers like Mears Machine to achieve new levels of productivity and innovation through additive manufacturing."

09:04 EDT Houlihan Lokey announces Kraft has joined as Managing Director - Houlihan Lokey announced that Kenny Kraft has joined the firm's Consumer, Food & Retail Group as a Managing Director. Based in Atlanta, Kraft will oversee the firm's coverage efforts across the retail and multi-unit sector, adding expertise in convenience stores, restaurants, and auto-related multi-unit companies.

13:03 EDT America Movil to acquire a controlling interest in ClaroVTR - America Movil (AMX) and Liberty Latin America (LILA) announce that, subject to obtaining the required approval from the National Economic Prosecutor's Office of the Republic of Chile, America Movil will be consolidating ClaroVTR into its ongoing operations. As previously disclosed, AMX has been providing funding to ClaroVTR through convertible notes to support the execution of its business plan and for the refinancing of certain bank debt existing at the formation of the JV and Liberty Latin America had the right to catch-up its respective portion of such funding commitments by the middle of this year for ClaroVTR to continue as a 50:50 joint venture.

09:03 EDT HUB Security 'on track' to release financial reports within next few weeks - HUB Cyber Security released the following statement regarding the recent announcement published on May 23, 2024: "The Company is on track to release its annual financial reports within the next few weeks. Additionally, the Company has recently secured two deals with governmental entities, highlighting its commitment to strategic expansion and enhancing its offerings. Looking ahead, the Company anticipates significant progress in its secure data fabric vertical by the end of the next quarter."

13:02 EDT Real Good Food launches Seasoned Chicken Breast Chunks in 4,000 Walmart stores - The Real Good Food Company (RGF) announced the national launch of its Garlic Parmesan and Lightly Buttered Seasoned Chicken Breast Chunks into the frozen poultry section of approximately 4,000 Walmart (WMT) stores nationwide.

09:01 EDT Actelis Networks expands with 'cyber-hardened IoT airport orders - Actelis Networks announced that it has received new orders to provide its cyber-hardened hybrid-fiber networking solution for international airports based in India, Japan, and Poland. These orders are part of its previously announced multi-year contract with SITA, a global leader in airport operations management systems. This announcement follows a number of recent achievements announced just in the past few weeks, including new orders received from three military bases, a recently announced partnership with Carahsoft to expand Actelis' footprint in US Government Agencies, and a new order and delivery to the City of Bakersfield, California..."We are very proud of the continued expansion of our cutting-edge solutions across international airport networks globally through our partnership with SITA," reflects Tuvia Barlev, Chairman and CEO of Actelis. "As the IoT industry rapidly expands and cyber threats grow, Actelis is in a unique position to help the industry quickly move forward, with both cost-effective, smart IoT implementation, as well as cybersecurity enhancement to legacy networks. Our work with SITA is a great example of Actelis' hybrid-fiber networking offering being introduced into the worldwide market, with a global operator, thus making a difference across an entire industry. With Actelis' solutions, SITA can implement its vision of operational excellence, and enhanced cybersecurity in Airports across the globe, on time and under budget."

09:00 EDT Akebia names Erik Ostrowski as CFO, Chief Business Officer - Akebia Therapeutics announced the appointment of Erik Ostrowski as Senior Vice President, CFO and Chief Business Officer. Ostrowski is an experienced biotech executive with a diverse background spanning industry leadership roles, board service and investment banking. Ostrowski joins Akebia from Avrobio, where he served as President, Interim CEO and CFO, leading the execution of its merger with Tectonic Therapeutic.

08:58 EDT BARDA selects Edesa Biotech drug for U.S. funded platform trial in ARDS - Edesa Biotech announced that its first-in-class drug candidate has been selected by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for evaluation in a U.S. government-funded clinical study. Edesa's drug paridiprubart represents a new class of HDTs that are designed to modulate the body's own immune response when confronted with known or unknown public health threats such as pandemic influenza, COVID-19, other emerging infectious diseases, and chemical, biological, radiological, and nuclear incidents. Importantly, HDTs are agnostic to the causal agent and can be stockpiled preemptively to respond to public health emergencies and biodefense. The BARDA-funded Phase 2 platform trial will be a randomized, double-blinded, placebo-controlled, multi-center U.S. clinical trial to investigate three novel threat-agnostic host-directed therapeutics, including paridiprubart, in hospitalized adult patients with ARDS. The BARDA study of paridiprubart is expected to build on the success of a Phase 2 clinical study that the company completed during the COVID-19 pandemic which demonstrated that paridiprubart reduced mortality by 84% among critically ill ARDS patients. A parallel study using an in vitro model also demonstrated that paridiprubart inhibits a key mediator of inflammatory responses from influenza and other pathogens. A separate Edesa-sponsored Phase 3 study of paridiprubart in patients with ARDS due to SARS-CoV-2 infection is currently ongoing in Canada and the U.S. The BARDA-funded study will be managed under a BARDA contract with PPD Development, LP, a clinical research business of Thermo Fisher Scientific, Inc. For the paridiprubart cohort of the study, patients will be randomized one-to-one to either paridiprubart plus Standard of Care or to a placebo plus SOC control arm. Edesa will provide drug products to the study as well as technical support

08:55 EDT Principal Solar partner eTruck to deploy hybrid-converted semis by year-end - Principal Solar announced that its Royalty Agreement Partner, eTruck Transportation, expects to begin producing powertrains that turn Class 8 diesel trucks into hybrid battery-electric vehicles by the end of 2024. The powertrain systems are already available for order, and eTruck plans to start commercial production by the end of the year, eTruck company President Russell Knudsen told Transport Topics.

08:53 EDT Biofrontera Inc. announces launch of RhodoLED XL lamp - Biofrontera announced the launch of its FDA-approved RhodoLED XL, a red light emitting LED lamp. This device represents a significant advancement in the treatment of PDT with state-of-the-art engineering, robust but sleek construction and an intuitive user interface. It is designed to be simple to maneuver and able to accommodate various patient treatment positions in order to optimize ease of use. Biofrontera's PDT drug, Ameluz, is approved by the FDA in combination with either member of the RhodoLED lamp family. The introduction of the RhodoLED XL provides the option to illuminate a larger area in a single on-label Ameluz PDT treatment.

08:51 EDT Matinas BioPharma reports treatment of patient with mucor infection with MAT2203 - Matinas BioPharma Holdings announces the recent treatment of a 22-year-old male with polymicrobial necrotizing fasciitis that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow. A total of 24 patients are currently receiving or have completed treatment with MAT2203 under the Compassionate/Expanded Use Access Program, and four additional cases are awaiting submission and/or FDA approval. In each instance, the patient was not responding to azole therapy, was unable to receive azole therapy due to drug/drug interactions or was unable to tolerate IV-amphotericin B for an appropriate treatment duration due to toxicity. In all patients who experienced serious renal toxicity while receiving IV-amphotericin B who were subsequently treated with MAT2203, renal toxicity was reversed, and renal function returned to baseline.

08:50 EDT Imunon announces database kock for Phase 2 studyof IMNN-001 in OC - IMUNON announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer. Median Overall Survival OS and Progression Free Survival PFS have been reached and all patients in the open-label study have achieved treatment observation duration of 16 months, as required per protocol to evaluate efficacy. The independent statisticians have received the raw trial data and will follow the statistical analysis plan as they analyze the data from the trial. IMUNON expects to report topline results including hazard ratios before the end of July 2024. OVATION 2 is evaluating the dosing, safety, efficacy and biological activity of intraperitoneal administration of IMNN-001 in combination with neoadjuvant chemotherapy NACT in patients newly diagnosed with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy. Following NACT, patients undergo interval debulking surgery, followed by three additional cycles of adjuvant chemotherapy to treat any residual tumor. Patients were randomized 1:1 and evaluated for safety and efficacy to compare NACT plus IMNN-001 versus standard-of-care NACT. Patients randomized to the IMNN-001 treatment arm received up to 17 doses of 100 mg/m2, in addition to NACT. Full enrollment of 110 patients was reached in September 2022.

08:49 EDT Nano Nuclear Energy acquires novel ALIP intellectual property - NANO Nuclear Energy announced its acquisition of novel annular linear induction pump intellectual property used in small nuclear reactor cooling and heat transfer from noted physicist, research engineer and project manager Carlos O. Maidana, PhD. of Maidana Research. Dr. Maidana has agreed to collaborate with NANO Nuclear as a consultant on further development of the ALIP technology with a view towards achieving SBIR Phase III Award status. These efforts will build on previous Department of Energy grants for the technology, aggregating over $1.37 million in prior phases. NANO Nuclear will provide funding and other resources necessary for the Phase III project, and Dr. Maidana will be the Principal Investigator on this project. The ALIP technology, which is based on electromagnetic pumps, is a key-enabling technology to NANO Nuclear's ODIN', a clean energy, portable micro nuclear reactor in development. Following the previously announced completion of Idaho National Laboratory's review of the 'ODIN' microreactor design in February 2024, NANO Nuclear engineers have diligently worked to identify relevant technologies to further optimize and simplify ODIN's design. The acquired ALIP technology, to be refined during the SBIR Phase III program, is an example of this strategy in action.

08:47 EDT Lead Real Estate announces plans for construction of 'Premium Series' hotel - Lead Real Estate announced plans to build the ENT TERRACE brand's first "Premium Series" hotel, ENT TERRACE GINZA PREMIUM, in Tokyo, Japan. The upcoming facility will have seven floors and six guest rooms, and accommodate from one night to long-term stays beginning in December 2024. Located about two minutes by walk from Higashi-Ginza Station on the Toei Asakusa Line. The current weak yen and increasing foreign interest in Japan, said LRE, are expected to continue their positive impact on the Company's expanding long-stay business.

08:46 EDT Anixa Biosciences treats sixth patient in ovarian cancer CAR-T clinical trial - Anixa Biosciences announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell therapy for ovarian cancer. This patient is expected to be the last patient in the second dosage cohort. If there continue to be no adverse effects experienced by the second cohort participants, enrollment of the third dosage cohort may commence within the next month. The study is being conducted through a research partnership with Moffitt Cancer Center.

08:45 EDT AST SpaceMobile welcomes Sambar to board of directors - AST SpaceMobile announced the appointment of Chris Sambar to its Board of Directors, effective June 20, succeeding Alex Coleman, Chairman at New Providence Acquisition Corp. Sambar brings a distinguished career in leadership and technology to AST SpaceMobile, further strengthening the company's expertise as it prepares for its next phase of growth.

08:45 EDT OSI Systems receives $11M order for mobile cargo, vehicle inspection systems - OSI Systems announced that its Security division received an order valued at approximately $11M to provide multiple units of the Eagle M60 mobile high-energy cargo and vehicle inspection system, including follow-on maintenance and support. The inspection systems are expected to be used for international border and security requirements. OSI Systems' Chairman and CEO, Deepak Chopra, stated, "We are thrilled to receive this award as it highlights the trust and confidence in our advanced inspection technologies. The Eagle M60 platform offers tremendous flexibility, allowing users to swiftly relocate checkpoints to enhance security measures efficiently."

08:43 EDT Creative Medical Technology announces development of IPSCelz program - Creative Medical Technology Holdings has generated human induced pluripotent stem cells-derived Islet Cells that produce human insulin. The iPSC clinical line that generated these insulin producing Islet Cells is part of the Company's iPSCelz program, which is validated by Greenstone Biosciences. The iPSC clinical line, which is currently utilized in a number of our FDA cleared clinical programs in the U.S., has also been utilized to derive validated mesenchymal cells and T-regulatory cells.

08:40 EDT Highest Performances says Puyi Fund asset allocation portfolio exceeded RMB24B - Highest Performances Holdings announced that the portfolio balance of the asset allocation services of its majority-owned subsidiary Fanhua Puyi Fund Distribution has reached RMB24.7 billion as of June 21, 2024, representing a year-over-year growth of 188% from June in 2023. This achievement stems from its relentless efforts in product strategy adjustments and digital transformation. The Company introduced a comprehensive family wealth management account system, shifting its focus to fixed-income fund products and fund portfolio products to offer clients a more stable and secure wealth-building experience. It recommends investors allocate 50% to 80% of their funds to "Steady Growth" accounts, aiming for steady asset appreciation while minimizing risks. This approach aligns with the current market trend in China, where investors are more inclined to a lower risk appetite.

08:38 EDT Saputo completes sale of two fresh milk processing facilities in Australia - Saputo has completed the previously announced sale of two fresh milk processing facilities located in Laverton North, Victoria, and Erskine Park, New South Wales, to Coles Group Limited, an Australian-based supermarket, retail, and consumer services chain, in a transaction valued at approximately CDN$95 million. The completion of this transaction is part of the Company's overall network optimization strategy, one of the pillars of its Global Strategic Plan. As part of the sale, Saputo is maintaining its valued farmer relationships in Australia and will continue to have fresh milk products processed at the two manufacturing facilities. The employment of approximately 48 people across the two sites was transferred to Coles Group Limited.

08:36 EDT Nuburu announces 1-for-40 reverse stock split - NUBURU announced that it will continue its previously announced plan to implement a 1-for-40 reverse stock split of its common stock, with an anticipated implementation date of July 1, 2024, rather than the previously announced June 24, 2024 anticipated implementation date. Due to the NYSE halting trading in the common stock upon the initial announcement of the Reverse Split, the Company was unable to implement the Reverse Split as announced. The Company is in the process of appealing the NYSE's determination to initiate proceedings to delist its common stock and is being traded on the over-the-counter market under the symbol "BURU" in the meantime. "Our decision to execute this reverse stock split is part of our strategic plan to improve the marketability and liquidity of our stock, as we aim to attract a broader range of institutional investors in support of our long-term growth strategy, and return to trading on NYSE American," said Brian Knaley, CEO of NUBURU, Inc.

08:35 EDT Silence Therapeutics achieves $2M research milestone payment from Hansoh Pharma - Silence Therapeutics announced that it will receive a $2M cash payment from Hansoh Pharmaceutical Group Company Limited following the achievement of a second undisclosed milestone related to the first target under the collaboration. "This represents an important milestone in our efforts to advance this program into the clinic with Hansoh," said Craig Tooman, President and CEO of Silence. "This is an exciting time for Silence and our mRNAi GOLD platform as we continue to advance and expand our pipeline targeting a wide range of genetic diseases."

12:33 EDT ODP and Telos announce new TSA PreCheck enrollment locations - Office Depot, an operating company of The ODP Corporation (ODP)and a leading omnichannel retailer dedicated to helping its small business, home office and education customers live more productive and organized lives, and Telos Corporation (TLS), an authorized TSA PreCheck enrollment provider, today announced additional TSA PreCheck enrollment locations with the opening of five new locations at Office Depot retail stores in Georgia, Tennessee and Texas beginning on June 2 . This follows the previous addition of 20 new locations since May 2024 in states including Arizona, California, Colorado, Texas and Washington.="Aligned with our focus on providing a variety of solutions to our clients, we are excited to partner with Telos Corporation to provide TSA PreCheck enrollment services," said Kevin Moffitt, executive vice president of The ODP Corporation and president of Office Depot. "Providing the convenience and ease to enroll in the TSA PreCheck program through our nationwide retail store locations is ideal for anyone looking to simplify their air travel experience. We are excited to expand this service, along with other travel essentials, to more stores in the near future."

08:33 EDT Mira Pharmaceuticals announces new results for Ketamir-2 - Mira Pharmaceuticals announced new compelling preclinical results for its investigational compound, Ketamir-2, a novel oral ketamine analog. The new data highlights Ketamir's potential to provide therapeutic benefits without inducing schizophrenia-like behavior or hyper-locomotor activity. MIRA conducted the latest rigorous preclinical studies in collaboration with Biotrial to evaluate the effects of Ketamir-2 on spontaneous locomotor activity in mice. The studies are particularly significant for the treatment of mental health disorders and pain management, presenting a major advancement in the development of safer and more effective therapeutic options. Key findings from the study: Reduced Psychotic-like Symptoms: Unlike traditional ketamine, which resulted in marked and significant hyperlocomotion, Ketamir-2 did not produce incidences of inducing hyperlocomotion, schizophrenia-like behaviors in animal models, indicating a potentially safer profile for human patients, especially those with a predisposition to psychotic disorders. No Hyper-locomotor Activity: The study showed that while traditional ketamine induced hyperlocomotion, Ketamir-2, at same and higher doses compared with traditional ketamine, did not result in the hyper-locomotor activity, reducing the potential for misuse and enhancing patient safety. MIRA is on track to submit an IND application for Ketamir-2 to the FDA by the end of this year.

08:29 EDT A-Mark acquires additional 8% interest in Silver Gold Bull for $9.6M - A-Mark Precious Metals has acquired an additional 8% of the outstanding equity interest in Calgary-based Silver Gold Bull for approximately $9.6 million. The investment brings A-Mark's ownership in SGB to 55.4% and continues to expand A-Mark's direct-to-consumer footprint in the international market. A-Mark acquired its initial stake in SGB in 2014, increasing its investment to 47.4% in 2022. Founded in 2009, SGB is a leading e-commerce precious metals retailer in Canada focused on providing online innovation, high-quality products, competitive pricing, and excellent customer service. Transaction Summary: A-Mark paid approximately $9.6 million for an additional 8% of the outstanding equity interest in SGB. A-Mark's previous option to increase its ownership interest in SGB has been reduced from 75% to 70%. The option, previously set to expire in September 2024, has been extended to September 2025. Employment agreements have been entered into with key SGB management, including Nikolas Morianos, Mihali Belandis and President and Co-Founder Bob Belandis. SGB financial and operational highlights for the fiscal year ended April 30, 2024, include: Net sales of $467.9 million, gross profit of $20.8 million and pre-tax income of $4.2 million. Sold more than 7.85 million ounces of silver and 151,000 ounces of gold. Added approximately 53,000 new customers, for a total of 520,000 customers as of April 30, 2024. Processed approximately 105,000 orders.

08:26 EDT Fangdd Network to acquire patents on cloud computer technology for $35M - Fangdd Network Group had entered into an agreement to purchase certain patents relating to cloud computer technology in China. The transaction is part of the Company's strategy to expand into technology-enabled real estate management as a supplement to its existing business. The purchase price for the patents is $35,000,000. Additionally, the seller is entitled to receive an earnout payment for each fiscal year ending on December 31, 2024, December 31, 2025 and December 31, 2026 at an amount equal to $15,000,000 multiplied by the ratio of the revenue generated by the patents during such year to RMB108,450,000. The total amount of the earnout payments for all three years combined shall not exceed $15,000,000. The Company will have three months to raise funds for the purchase and complete the transaction. If the transaction does not close by September 21, 2024, either party may terminate the agreement by providing written notice, without incurring liability to the other party. The purchase agreement contains representations, warranties and other provisions customary for transactions of this nature.

08:23 EDT Recursion Pharmaceuticals gives guidance on seven clinical readouts - Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will give updated pipeline guidance to investors, analysts, and other stakeholders during Download Day, Recursion's investor and R&D day, on Monday, June 24, 2024. The event will feature a number of prominent speakers, including Jensen Huang, founder and CEO of NVIDIA, Deepak Nijhawan, M.D., Ph.D., UT Southwestern Distinguished Chair in Biomedical Science, and John Marioni, Ph.D., Senior VP and Head of Computational Sciences at Genentech. Updated pipeline guidance: Seven Clinical Trial Readouts expected within approximately 18 months: REC-994 Cerebral Cavernous Malformation-topline Phase 2 data readout in September 2024; REC-2282 Neurofibromatosis Type 2-preliminary Phase 2 data readout in the fourth quarter of 2024; REC-4881 Familial Adenomatous Polyposis-preliminary Phase 2 data readout in the first half of 2025; REC-4881 Advanced AXIN1/APC-Mutant Cancers-preliminary Phase 2 data readout in the first half of 2025; REC-3964 Clostridioides difficile Infection-Phase 2 study initiation in the fourth quarter of 2024 and preliminary data readout by the end of 2025; RBM39 Advanced HR-Proficient Cancers-IND submission in the third quarter of 2024, Phase 1/2 initiation in the fourth quarter of 2024 and Phase 1 dose-escalation data readout by the end of 2025; Target Epsilon-IND submission in early 2025 and Phase 1 healthy volunteer study data readout by the end of 2025. Dozens of internal and partner programs in early stages with the first LLM and causal model driven programs entering the Recursion pipeline. Partnership updates: Bayer will be the first beta-user of our LOWE LLM-orchestrated workflow software, which will be integrated across the collaboration and offer a more exploratory, and intuitive research environment for scientists on both sides. Additional updates pertaining to the Bayer partnership include: We initiated our first joint oncology project which is now expected to advance rapidly towards Lead Series nomination; and We are on track to complete 25 unique multi-modal data packages that we expect to deliver in the third quarter of 2024. Platform updates ADME industrialization: potential to achieve an estimated 90 times the amount of lab throughput over a manual approach. Built our first genome-scale transcriptomics knockout map. Multimodal mapping has enabled us in certain experiments to achieve 90% success on our ability to predict compounds that failed later disease-relevant assays in internal tests and 60% ability to predict compounds that passed later disease-relevant assays in internal tests. Helix partnership brings hundreds of thousands of unique de-identified patient records across diverse therapeutic areas.

08:20 EDT OneMedNet enters standby equity purchase agreement with Yorkville - As previously disclosed on Form 8-K filed with the SEC on June 21, 2024, the Company entered into a standby equity purchase agreement with YA II PN, LTD, a Cayman Islands exempt limited partnership managed by Yorkville Advisors Global,, on June 17, 2024. Under the terms of the SEPA, Yorkville committed to purchase up to $25.0 million of the Company's common stock over the next twenty-four-month period, subject to certain conditions and limitations. The purchase price will be at a 3.0% discount. On June 18, 2024, Yorkville advanced $1.5 million to the Company under a convertible promissory note due June 18, 2025. Generally, the Company anticipates that the note will be repaid through SEPA advances initiated by Yorkville at the note conversion price, which will be then applied to the outstanding balance. The Company's right to draw on the SEPA will begin after repayment of the Promissory Note. The Company intends to use the proceeds from the promissory note and the potential offering of the common shares pursuant to the SEPA for working capital and other general corporate purposes. The SEPA supersedes and replaces the Company's definitive securities purchase agreement with Helena Global Investment Opportunities 1 Ltd., which had provided for up to $4.54 million in funding through a private placement for the issuance of senior secured convertible notes, which was terminated on June 14, 2024.

08:18 EDT OneMedNet provides update on auditor change - OneMedNet Corporation provided a number of corporate updates. As previously disclosed via a Form 8-K filed by the Company with the Securities and Exchange Commission on May 10, 2024, on May 6, 2024, the Company dismissed BF Borgers CPA PC as its independent registered public accounting firm. On May 3, 2024, the SEC announced that it had settled charges against Borgers that it failed to conduct audits of a number of public companies in accordance with the standards of the Public Company Accounting Oversight Board. As part of the settlement, BF Borgers agreed to a permanent ban on appearing or practicing before the SEC. On June 3, 2024, the Company appointed WithumSmith+Brown, PC as its new independent registered public accounting firm to audit and review the Company's financial statements.

08:16 EDT CervoMed announces addition to Russell 2000, Russell 3000 Indexes - CervoMed announced its expected addition to the Russell 2000 and Russell 3000 Indexes at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective when the U.S. equity markets open on Monday, July 1, 2024, according to the final preliminary list of 2024 additions posted on the FTSE Russell website on June 21st 2024.

08:16 EDT Stratasys, AM Craft partner to drive growth in 3D manufacturing for aviation - Stratasys and aviation manufacturing pioneer AM Craft announced that they are partnering to align the two companies' efforts to grow the demand for flight-certified 3D printed parts in the aviation industry. The companies signed a definitive commercial collaboration agreement, along with Stratasys' strategic investment in AM Craft.

08:15 EDT Yatra announces independent committee to evaluate potential restructuring - Yatra Online announced that its board of directors is looking to explore certain strategic options regarding simplifying the Company's multi-jurisdictional corporate structure and in that direction has established an independent committee of the board. The committee is expected to engage with industry experts, legal counsel, regulatory bodies, and other stakeholders to gather insights, perspectives, and requirements for approval on any proposed corporate structural changes. After such review, the committee will develop a set of strategic recommendations for the board that outline potential pathways, the anticipated benefits, and any associated risks or challenges. The committee will aim for a plan that can reduce administrative overhead, rationalize costs, and facilitate organic and inorganic growth for the Company. There is no assurance that the Company will necessarily take any near-term course of action, or will pursue any recommended plan.

08:14 EDT Kiniksa, NHL Hall-of-Famer Henrik Lundqvist partner for pericarditis awareness - Kiniksa Pharmaceuticals announced a partnership with National Hockey League Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease. The campaign will kick off in September of this year.

08:13 EDT Crowdstrike will be added to the S&P 500 Index - CrowdStrike will be added to the S&P 500 Index, making CrowdStrike the fastest cybersecurity company to attain this achievement. CrowdStrike's inclusion in the S&P 500 reflects its track record of industry leadership and innovation, transforming cybersecurity with AI through a single platform that stops breaches. CrowdStrike brought SaaS cybersecurity to the cloud, natively built the Falcon platform with AI from the start and has consistently delivered hyper growth results since its blockbuster 2019 IPO.

12:12 EDT Walgreens optimized operations with Zebra's Workcloud Software - Zebra Technologies (ZBRA) announced that the Walgreens (WBA) Boots Alliance has optimized its operations with Zebra Workcloud Actionable Intelligence software to save millions of dollars by enhancing operational compliance and the company's ability to identify and combat shrink. Walgreens selected Zebra's Modern Store framework to improve asset protection, better equip employees with technology, and optimize operational visibility in their network of 8,000 locations across 50 states. As an essential retailer carrying critical healthcare products and prescription medications, Walgreens needed an intuitive analytics solution to uncover issues and resolve areas of loss in real time.

08:10 EDT One Energy select Cuffe to join One Power Board at business combination closing - One Energy Enterprises, an industrial power company pursuing a business combination transaction with TortoiseEcofin Acquisition Corp. III, announced its selection of Selena Cuffe to join the board of directors of the surviving public company after the proposed business combination, which is expected to be renamed One Power Company. Prior to consummating the Business Combination, TRTL will seek shareholder approval of the transaction, including the appointment of Cuffe and the other director nominees to the One Power Board.

12:09 EDT Soluna Holdings unleashes first batch of NVIDIA GPUs - Soluna (SLNH) announced it has successfully raised a credit facility of $12.5M at its new subsidiary Soluna Cloud, marking the completion of the first tranche in a larger fundraising effort led by BitOoda Technologies and Imperial Capital. This financing will support the launch of Soluna Cloud, and secure NVIDIA H100 (NVDA) GPUs leveraging a 3-year managed-services agreement at a Tier 3 hydro-powered data center in collaboration with the Company's Strategic OEM Partner. "This is a pivotal point for Soluna Cloud as we are now able to open our waitlist for this highly anticipated business at Soluna. AI is set to transform the enterprise, and Soluna is making a vital contribution to making it a climate-friendly reality," said John Belizaire, CEO of Soluna.

12:07 EDT Byrna Technologies names Lauri Kearnes as Chief Financial Officer - Byrna Technologies (BYRN) has appointed Lauri Kearnes as Chief Financial Officer CFO , effective July 15...Kearnes is already working with the Company to ensure a smooth transition. Kearnes brings over 20 years of experience in financial and operating leadership, most recently serving as CFO for Harte Hanks (HHS), a Massachusetts-based global customer experience strategy company. At Harte Hanks, she oversaw all finance, accounting, and human resources for a business with over $200 million in annual revenues.

08:06 EDT Enlivex Therapeutics doses first patient in Phase I/II trial of Allocetra - Enlivex Therapeutics announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I/II trial evaluating the efficacy and safety of Allocetra following injection into patients with basal thumb joint osteoarthritis, for which conventional therapies have failed. This investigator-initiated Phase I/II trial plans to recruit up to 46 patients and is composed of two stages. The first stage is a safety run-in, open-label dose escalation phase to characterize the safety and tolerability of an Allocetra injection in patients with osteoarthritis of the first basal thumb joint of the target thumb to identify the dose for the randomized stage. The second stage is a double-blind, randomized, placebo-controlled stage, which the Company expects to initiate following the completion of the safety run-in stage and selection of the safe and tolerable dose. Up to 40 patients will be randomized in a 1:1 ratio for treatment with either Allocetra at the selected dose or placebo. The primary safety endpoint will measure the frequency and severity of adverse events and serious adverse events, and the efficacy endpoints will include assessments of change from baseline in pain and function for up to 12 months following treatment.

08:05 EDT Seven Hills Realty Trust announces it will be added to Russell 3000 Index - Seven Hills Realty Trust announced that it will be added to the broad-market Russell 3000 Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective after market close of the U.S. equity markets on Friday, June 28, 2024, according to a preliminary list of additions posted by FTSE Russell on June 21, 2024.

08:04 EDT Evolus announces submission of PMA to U.S. FDA for two Evolysse products - Evolus announced that it has submitted the final module of its premarket approval, PMA, application to the U.S. Food and Drug Administration, FDA, for the Evolysse Lift and Evolysse Smooth dermal filler products for the nasolabial fold, NLF. The PMA application includes results from the U.S. pivotal study, which evaluated the safety and effectiveness of the products in a multicenter, blinded, split face, controlled, non-inferiority designed trial. Patients were followed for 12 months from initial treatment. A total of 140 patients were enrolled and divided evenly across two investigational arms. Patients were randomized to receive Evolysse Lift or Evolysse Smooth in one NLF and Restylane-L in the contralateral NLF. This split face design allowed each individual patient to experience one of the Evolysse fillers and the control at the same time.

08:03 EDT PetMed Express appoints Leah Solivan to board of directors - PetMed Express announced the appointment of Leah Solivan to the Company's Board of Directors, effective June 24, 2024. Solivan brings over 20 years of experience building and scaling technology businesses to the Company's Board. As a General Partner at Fuel Capital, she focuses on early-stage investments across a variety of sectors, including consumer technology, hardware, education, marketplaces, and retail.

08:01 EDT Taoping receives Nasdaq notice of non-compliance - Taoping announced that on June 21, 2024, it received a written notification letter from The Nasdaq Stock Market notifying the company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

08:00 EDT CSG increases purchase price for The Kinetic Group to $2B - Vista Outdoor announced that, on June 23, 2024, it entered into an amendment to the merger agreement with Czechoslovak Group, CSG. The amended agreement further increases the base purchase price payable by CSG for the acquisition of The Kinetic Group business by $40 million from $1.96 billion to $2 billion and increases the cash consideration payable to Vista Outdoor stockholders by $2.00 per share of Vista Outdoor common stock from $16.00 to $18.00 in cash, a 12.5% increase. Based on the amended merger agreement with CSG, Vista Outdoor stockholders will receive at the closing of the CSG Transaction, per share of Vista Outdoor common stock, one share of Revelyst common stock and $18.00 in cash. Vista Outdoor is confident that the CSG Transaction will maximize value for our stockholders by: Providing for a $2 billion purchase price, representing a $90 million increase from the original $1.91 billion purchase price, Allowing stockholders to benefit directly from additional excess cash generated by the Company prior to closing, Delivering $18.00 in cash consideration per share at closing, representing a $5.10 increase from the original cash consideration of $12.90 per share, and Enabling stockholders to capture the long-term intrinsic value that is embedded in Revelyst's business plan as a standalone public company

07:58 EDT Biogen announces Tofidence biosimilar approved in European Union - Biogen announced that the European Commission has granted approval for TOFIDENCE, a biosimilar monoclonal antibody referencing ROACTEMRA. The intravenous formulation of TOFIDENCE has been granted marketing authorization by the EC for the treatment of moderate to severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis and COVID-19. "The approval of TOFIDENCE offers European patients with several inflammatory and immune-mediated inflammatory diseases access to an additional affordable biologic treatment option with comparable safety and efficacy to the approved reference product. By adding TOFIDENCE to our growing biosimilars portfolio, we can provide greater choice to physicians and patients whilst offering the potential for significant cost-savings across healthcare systems in Europe," said Ian Henshaw, Global Head of Biosimilars at Biogen.

07:41 EDT Envela's Four Nines opens flagship store in Phoenix - Four Nines opened its latest store in Phoenix, Arizona. "As we continue to expand our retail presence, our team remains laser focused on delivering exceptional experiences and value for our customers. Our store experience is defined by our team of experts and exceptional services, distinguishing us from others in the industry. We are excited to announce the opening of our largest store in Arizona, which will provide an expanded range of products and services for both buyers and sellers," stated Allison DeStefano, Head of Envela's Consumer Division.

07:38 EDT FirstService Residential acquires CitiScape Property Managment Group - FirstService Residential has acquired San Francisco-based CitiScape Property Management Group. CitiScape's existing executive team will continue to lead day-to-day operations. Terms of the transaction were not disclosed. Founded in 1999, CitiScape is a leading full-service community association management firm in the San Francisco metropolitan market, providing a range of property management and project management services to high-rise condominium and homeowner association clients. The acquisition solidifies FirstService Residential's market leadership in the Bay Area of Northern California.

07:37 EDT Checkpoint announces FDA alignment enabling cosibelimab BLA resubmission - Checkpoint Therapeutics reached alignment with the Food and Drug Administration on its biologics license application resubmission strategy for cosibelimab. Accordingly, Checkpoint plans to move forward with a mid-year BLA resubmission seeking the U.S. marketing approval for cosibelimab as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. In December 2023, the FDA issued a CRL for the cosibelimab BLA, which only cited findings that arose during a multi-sponsor inspection of Checkpoint's third-party contract manufacturing organization as approvability issues to address in a BLA resubmission. The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.

07:35 EDT Dyne announces new Pompe disease data showing potential of FORCE platform - Dyne Therapeutics, announced new preclinical data in a Pompe disease model demonstrating the potential of the FORCE platform to deliver enzyme replacement therapy to cardiac and skeletal muscle and the central nervous system or CNS. The data were presented at the New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 23-26 in Fort Lauderdale, FL. "These preclinical data show for the first time the ability of FORCE to deliver enzymes to skeletal and cardiac muscle as well as the CNS, expanding the modularity of our platform beyond oligonucleotides. The data support the potential of FORCE to enable effective enzyme replacement therapy with the opportunity to substantially improve upon available treatments for Pompe disease," Oxana Beskrovnaya, Ph.D., chief scientific officer of Dyne. "We look forward to continuing to explore this application of our platform as part of our mission to deliver life-transforming therapies for people with serious muscle diseases." Pompe disease is a rare, severe neuromuscular disorder caused by deficiency of the lysosomal enzyme, acid alpha glucosidase or GAA. Lack of GAA leads to glycogen accumulation and increase in lysosomal size in muscle and subsequent weakness, cardiomyopathy and respiratory failure. Enzyme replacement therapy with GAA is the standard of care and increases survival but has inadequate efficacy in skeletal muscle. Pompe is also characterized by CNS manifestations, including behavioral and cognitive deficits due to glycogen accumulation in CNS cells, which are not addressed by the standard of care therapy.

07:32 EDT Arrowhead presents preclinical data on new ARO-INHBE - Arrowhead Pharmaceuticals announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association, ADA, 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been identified through large genetic studies as a promising target for next generation therapies to address obesity and metabolic diseases. Further, Arrowhead's preclinical research suggests that INHBE knockdown may potentially lead to a suppression in body weight gain, loss of fat mass, and preservation of lean mass. Arrowhead plans to file for regulatory clearance in late 2024 to begin clinical studies of ARO-INHBE.

07:31 EDT Spruce Power Holding appoints McBane as new Director - Spruce Power Holding announced that it has appointed Clara Nagy McBane to serve as a new member of its Board of Directors effective immediately. As a result, the Board has increased to seven members.

07:30 EDT Bowman Consulting selected to provide imagery services to State of Oregon - Bowman Consulting Group has been contracted by the State of Oregon to deliver 30 cm high-resolution natural color and false color infrared orthorectified digital imagery for the entire state. "This win is the direct result of our recent Surdex acquisition and reflects the synergies that the expanded capabilities of our now combined companies offer," said Gary Bowman, chairman and chief executive officer at Bowman. "We are appreciative of this award and look forward to supporting the State of Oregon in this initiative. We are confident that Bowman's extensive geospatial expertise and advanced high-altitude digital orthoimagery technologies will benefit agencies and governments not just across Oregon but in many other states as well."

07:21 EDT Alta Global partners with former UFC fighter Gilbert Melendez - Alta Global Group announced a new partnership with Gilbert Melendez, two-time Strikeforce Champion, former UFC Fighter and MMA Sports Commentator for ESPN. Melendez, a prominent figure in the world of mixed martial arts, brings a wealth of experience and a storied career to the Alta family. From Santa Ana, California, Melendez has been a leading name in MMA for years. Known by his moniker "El Nino", a nickname given by a Japanese broadcaster for his storm-like fighting style, Melendez has made a significant impact on the sport. Currently, Melendez is the head coach at El Nino Training Center in San Francisco, California, a long-standing partner of Alta. His dedication to training and mentoring the next generation of fighters aligns perfectly with Alta's mission to make the sport more accessible to fans across the globe.

07:14 EDT Sachem Capital announces repayment, delisting of unsubordinated notes from NYSE - Sachem Capital announced that the company intends to delist its 7.125% unsecured, unsubordinated Notes due June 30, 2024, ticker symbol "SCCB", from the NYSE American and to deregister the Notes under the Exchange Act of 1934, as amended. The company will redeem the Notes at par value plus accrued and unpaid interest up to, but not including, the maturity date. Sachem expects the last trading day for the Notes will be June 28, 2024. Sachem does not intend to arrange for listing and/or registration of the Notes on another national securities exchange or for quotation on another quotation medium.

07:13 EDT StorageVault Canada to acquire two locations for $59.5M - STORAGEVAULT CANADA has agreed to acquire two locations from two arm's length vendor groups for an aggregate purchase price of $59,500,000, subject to customary adjustments. One of the locations is being purchased under a 50/50 joint venture. StorageVault owns a self storage property that is nearby to the joint venture property and provides StorageVault the opportunity to expand its self storage business in that location. The aggregate purchase price is expected to be paid with funds on hand, issuance of 640,000 StorageVault common shares valued at $4,000,000 to one of the Vendors and a vendor takeback mortgage from one of the Vendors. The Acquisitions are expected to close by the end of June. Under the terms of the Joint Venture, the joint venture partner and StorageVault will each fund 50% of the purchase price of the Joint Venture location, which includes related expenditures. The Acquisitions are subject to customary closing conditions for both StorageVault and the Vendors. One of the assets are located in the GTA and one in Surrey, BC. The Acquisitions will result in StorageVault owning 218 stores and owning and managing 249 stores across Canada. Further to its November 6, 2023, December 8, 2023 and December 28, 2023 news releases, StorageVault has completed the acquisition of a Barrie, ON located asset for $15,500,000, subject to customary adjustments. The purchase price was paid with funds on hand. This transaction completes all of the transactions announced on November 6, 2023 news release. Further to its December 28, 2023 news release, due to not being able to satisfy itself with due diligence conditions, StorageVault has terminated the acquisition of the two storage locations in Ontario for $20,000,000. With the above two updates, the $35,500,000 of transactions outstanding from 2023 have been accounted for.

07:12 EDT Aya Gold & Silver reports final drawdown on Zgounder Mine loan - Aya Gold & Silver has completed its fourth and final drawdown under the previously announced US$100 million project financing facility for the expansion of the Zgounder Silver Mine in the Kingdom of Morocco. The Facility is jointly provided by the European Bank for Reconstruction and Development and by the Climate Investment Funds through its Clean Technology Fund. The fourth drawdown is in the amount of $15 million and brings the total drawn to date equal to the total of the available Facility at $100 million. The final drawdown followed an April technical site visit by the lenders and their technical advisor. Proceeds of this drawdown will be used to further advance the Zgounder Mine expansion project.

07:10 EDT Regenxbio expands Phase I/II AFFINITY DUCHENNE trial - Regenxbio announced it initiated enrollment in a new cohort of patients ages 1-3 in its Phase I/II AFFINITY DUCHENNE trial to evaluate the safety and efficacy of RGX-202 in boys with Duchenne muscular dystrophy. RGX-202 is an investigational one-time AAV Therapeutic targeted to deliver a novel microdystrophin, representing the next wave of innovative design in Duchenne gene therapy. RGX-202 is the only gene therapy approved or in development for Duchenne that incorporates the C-Terminal domain, making the RGX-202 transgene the closest to the naturally occurring dystrophin gene. With this announcement, REGENXBIO is enrolling ambulatory boys with Duchenne aged 1 to 11 in the AFFINITY DUCHENNE trial. The new cohort is expected to enroll up to five patients aged 1-3 to receive RGX-202 at the pivotal dose level (2x1014 genome copies.

07:10 EDT HeartFocus joins Butterfly Network's Butterfly Garden - HeartFocus announced it has joined Butterfly Garden, an artificial intelligence Marketplace launched by Butterfly Network, digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software. Under the agreement, HeartFocus plans to integrate, and with subsequent agreements, release its patented, AI-powered software with Butterfly's single-probe, whole-body handheld ultrasound system, subject to applicable approvals and authorizations.

07:09 EDT Alnylam reports results from its HELIOS-B Phase 3 study of vutrisiran - Alnylam Pharmaceuticals announced positive topline results from its HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy, ATTR-CM. The study met the primary endpoint, demonstrating a statistically significant reduction in the composite of all-cause mortality and recurrent cardiovascular events during the double-blind period in both the overall population and in the monotherapy population. The study also demonstrated statistically significant improvements across all secondary endpoints in both the overall and monotherapy populations. This includes key measures of disease progression: 6-minute walk test, Kansas City Cardiomyopathy Questionnaire and New York Heart Association Class at Month 30. Importantly, treatment with vutrisiran also reduced all-cause mortality in the overall population and in the monotherapy population up to Month 42. This was a pre-specified, intent-to-treat analysis that included up to six months of data from the open-label extension.

07:07 EDT Can-Fite BioPharma announces findings on Namodenoson - Can-Fite BioPharma announces that company scientists came up with breakthrough findings showing that the anti-cancer and protective effects in the liver are conferred via the signalling protein adiponectin. This very important positive cytokine plays a pivotal role in regulating anti-inflammatory, anti-cancer, metabolic and insulin resistance. Namodenoson increases adiponectin production in pre-clinical studies and in humans. "We are very much enthused by the breakthrough findings that explain the dual mechanism of Namodenoson working as an anti-cancer agent in the liver and also inducing a liver protective effect," stated Dr. Pnina Fishman, Can-Fite CSO & Chairperson.

07:07 EDT Adicet Bio announces FDA clearance of IND application for ADI-270 - Adicet Bio announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application to evaluate ADI-270, an armored allogeneic "off-the-shelf" gamma delta chimeric antigen receptor T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma, RCC. The Company plans to initiate a Phase 1 clinical trial to assess the safety and anti-tumor activity of ADI-270 in RCC patients in the second half of 2024.

07:06 EDT Orthofix named Finegan as Chair of the Board of Directors - Orthofix Medical announced the appointment of Michael Finegan as Chair of the Board of Directors. Finegan was appointed to the Orthofix Board in December 2023.

07:06 EDT Enbridge, Six Nations to advance wind energy project in Saskatchewan - Enbridge and Six Nations Energy Development - a newly-created consortium of Cowessess First Nation, George Gordon First Nation, Kahkewistahaw First Nation, Metis Nation-Saskatchewan, Pasqua First Nation and White Bear First Nations - announced plans to advance development of a new wind energy project southeast of Weyburn, Saskatchewan. The Seven Stars Energy Project is expected to produce 200 megawatts of emissions-free power - enough to support the annual energy needs of more than 100,000 Saskatchewan homes. It will be developed, constructed and operated by a wholly-owned indirect subsidiary of Enbridge. Financial participation of the partners will be supported, in part, by loan guarantees of up to $100M from the Saskatchewan Indigenous Investment Finance Corporation. The First Nation and Metis partners have an opportunity to acquire equity ownership of at least 30% in the Project. The Project is targeted to be operational in 2027, subject to finalizing commercial agreements, securing the necessary environmental and regulatory approvals, and meeting investment criteria. Enbridge is working toward securing a long-term power purchase agreement with SaskPower to support final investment decisions, anticipated in 2025.

07:04 EDT Scholar Rock announces new SRK-439 preclinical data - Scholar Rock announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin inhibitor, to preserve lean muscle mass in individuals living with obesity and on background therapy of a GLP-1 receptor agonist, GLP-1 RA. The trial will also evaluate the effects of apitegromab on the durability of weight loss upon withdrawal of GLP-1 RA therapy. The results from this trial will inform the development of SRK-439, a novel investigational selective myostatin inhibitor optimized for the treatment of cardiometabolic disorders, including obesity.

07:03 EDT Castle Biosciences announces latest AGA guideline on NDBE - Castle Biosciences announced that the latest American Gastroenterological Association, AGA, clinical practice guideline recognized that not all patients with non-dysplastic BE, NDBE, are at low risk of developing esophageal cancer. The guideline acknowledges the role that tissue-based biomarkers, including the tissue systems pathology test, can play in identifying high-risk NDBE patients who may benefit from endoscopic eradication therapy (EET) to prevent disease progression. In the recently published AGA guideline, the expert panel of authors acknowledge the role that tissue-based biomarkers can play in stratifying the large pool of patients with NDBE to help identity those at high risk of progression for consideration of treatment with EET at an early, precancerous stage.

07:03 EDT eFFECTOR to wind down operations, expects to be delisted from Nasdaq - eFFECTOR Therapeutics announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company's development programs. This decision was made at a special meeting of the board of directors. Further, as previously disclosed, the Company's securities do not presently meet the continued listing requirements of the Nasdaq Stock Market and its securities would be subject to delisting if the Company fails to regain compliance during the required compliance period. The Company plans to voluntarily request a delisting of its securities and expects its securities to be delisted in the near term. The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987.

07:02 EDT GM Financial Bank withdraws application for deposit insurance - General Motors Financial, the finance subsidiary of General Motors, has announced the withdrawal of GM Financial Bank's Interagency Charter and Federal Deposit Insurance Application from further processing by the Federal Deposit Insurance Corporation, FDIC. The application was submitted in late 2020 to both the FDIC and Utah Department of Financial Institution, UDFI. Throughout this more than three-year process, GM Financial Bank has worked constructively and transparently to promptly address all regulatory requests and has developed a strong charter application that satisfies the statutory criteria for approval in the Federal Deposit Insurance Act. The business model is also already in effect for several existing FDIC-insured industrial banks, including other auto manufacturers, but currently excludes American auto manufacturers. On June 14, 2024, the UDFI approved GM Financial Bank's application, appropriately underscoring the strength of the application and the conclusion that General Motors has the financial resources needed to operate an industrial bank in a safe and sound manner and in full compliance with applicable laws and regulations.

11:01 EDT Altair Engineering signs material agreement with HP Inc. - Altair (ALTR) has signed an agreement with HP Inc. (HPQ) in which HP will provide Altair with proprietary material information that will bolster the Altair Material Data Center, which enables designers, engineers, and scientists to browse, search, and compare materials in a standalone application or through the interface of their simulation and optimization tools. The collaboration will help break down traditional barriers to 3D printing adoption and ultimately help customers better design parts for Multi Jet Fusion and Metal Jet printers.

10:55 EDT ANI Pharmaceuticals sees 'substantial accretion' from Alimera Sciences deal - ANI expects high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and substantial accretion thereafter. The transaction is anticipated to deliver additional $35M-$38M in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10M in identified cost synergies with additional EBITDA contribution expected from accelerated growth of Cortrophin Gel within ophthalmology. The company anticipates 3.2x pro-forma leverage upon closing and significant organic de-levering in 2025.

10:53 EDT ANI Pharmaceuticals to acquire Alimera Sciences for $381M upfront - ANI Pharmaceuticals (ANIP) and Alimera Sciences (ALIM) announced they have signed a definitive agreement pursuant to which ANI will acquire Alimera for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027. The transaction, which values Alimera at approximately $381M in up front consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024.

06:48 EDT J.Jill executes voluntary debt principal payment - J.Jill announced that it has executed a voluntary debt principal payment using net proceeds to the company of $31M from its primary equity offering completed on June 14, 2024. The debt principal repaid on June 21, 2024 was $27.2M, which reduced the amount outstanding under the company's term loan to approximately $81M. In addition to the principal, accrued interest and a 3% voluntary premium were paid resulting in a total payment of $28.8M.

06:47 EDT Canada Nickel announces $15M loan facility with Auramet - Canada Nickel Company announces that the Company has arranged a $15M loan facility with Auramet, which is expected to close on or before July 9, 2024. Mark Selby, CEO, said, "I am pleased that our long supportive financing partner, Auramet, has agreed to provide a $15M bridge facility, which will allow us to remain well-funded to continue to advance our permitting, engineering, and financing activities. Discussions with offtake and project partners for Crawford are ongoing and expected to be completed before year end as we continue to target a mid-year 2025 construction decision for Crawford upon receipt of permits." The loan will be due January 9, 2025, will carry an interest rate of 1.00% per month, and be subject to a 2.5% arrangement fee. At closing, Auramet will also receive 750,000 1 year warrants with a strike price of $1.42. The loan will be subject to such terms and conditions including certain specified positive and negative covenants that are customary for a transaction of this nature. The warrants and the underlying shares will be subject to a four month hold period under applicable Canadian securities laws. The proceeds will be used for working capital purposes. The closing of the loan facility is subject to customary conditions including the approval of the TSX Venture Exchange.

06:45 EDT Ares Management invests in Unrivaled Sports' action sports division - Unrivaled Sports has made a strategic investment in SNOBAHN, the nation's indoor action sports center with two locations in Colorado. Additionally, the company announced a strategic investment in its action sports division by Ares Management funds. Ares' investment enhances a team that includes snowboarding legend Shaun White, The Chernin Group, and Unrivaled Sports co-founders Josh Harris and David Blitzer. Unrivaled Sports is committed to expanding SNOBAHN into new markets, making action and snow sports more accessible to a wider audience in the years ahead. Founded in 2016, SNOBAHN's facilities are the most efficient, effective, and affordable way to learn or advance skills in skiing, snowboarding, skateboarding, and BMX. SNOBAHN eliminates the geographical barriers traditionally associated with learning snow sports through features like revolving slopes and trampoline freestyle areas. Bode Miller, an Olympic and World Championship gold medalist in alpine skiing, is an existing partner of SNOBAHN. Miller was part of the grand opening ceremonies that took place at SNOBAHN's newest location in Thornton, Colo., in March 2024.

06:32 EDT G1 Therapeutics provides update on Phase 3 PRESERVE 2 trial of trilaciclib - G1 Therapeutics announced topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of trilaciclib administered prior to chemotherapy in patients with metastatic TNBC. The study did not demonstrate a statistically significant treatment effect in the ITT population with a hazard ratio of 0.91. The median OS in the trilaciclib plus GCb arm was 17.4 months compared to 17.8 months in the control arm. Median OS numerically favored the trilaciclib arm in both PD-L1 subgroups (positive and negative), though neither achieved statistical significance. Varying effects were observed across regions and patients who received different types of subsequent therapies; these findings will be evaluated further. The safety profile of trilaciclib with GCb observed in the trial was consistent with prior studies, and no new safety signals were identified. Consistent with other trilaciclib studies, evidence of myeloprotection was observed, including a reduction in the occurrence of severe neutropenia, which occurred in 8% of patients who received trilaciclib compared to 29% of patients in the control arm. The company will submit the results of this trial to a future medical conference. "The unexpected results from PRESERVE 2 underscore the challenge of developing new therapies for triple negative breast cancer," said Jack Bailey, CEO of G1 Therapeutics. "We are disappointed that this trial did not deliver the benefit that we anticipated to people living with TNBC. We are also grateful to the patients who participated in this trial, their families, and their healthcare teams including the clinicians and their staff." Bailey continued, "We will now further our focus on both accelerating and expanding the growth of the ES-SCLC business to achieve anticipated company profitability in the second half of 2025 and evaluating other myeloprotection uses for trilaciclib. We are also pursuing ex-US partners to expand the use of COSELA globally."

06:25 EDT GSK announces Omjjara approved in Japan for myelofibrosis - GSK plc announced that Japan's Ministry of Health, Labour and Welfare, or MHLW, has approved Omjjara for the treatment of myelofibrosis. Omjjara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 inhibitor. The approval is based on data from the pivotal phase III MOMENTUM and SIMPLIFY-1 trials. "This is the fourth major regulatory approval for GSK's momelotinib in the treatment of myelofibrosis, following approval under the brand name Ojjaara from the US Food and Drug Administration and authorisations under the brand name Omjjara from the European Commission and the Medicines and Healthcare products Regulatory Agency in the UK," the company stated. Nina Mojas, Senior Vice President, Oncology Global Product Strategy, GSK, said: "Myelofibrosis has a heavy disease burden, with symptomatic patients experiencing spleen enlargement, fatigue, night sweats and bone pain, along with anaemia which can lead to treatment discontinuation and dependence on regular blood transfusions. With the approval of Omjjara, myelofibrosis patients in Japan will have a new treatment option for this complex blood cancer."

06:18 EDT RamSoft, Upland announce 40M faxes sent via PowerServer, InterFAX solution - RamSoft in partnership with Upland Software announces the milestone transmission of the 40 millionth fax through the integration of RamSoft PowerServer and Upland InterFAX. InterFAX, Upland's cloud-based fax and digital workflow solution known for its robust security features including PHIPA and HIPAA compliance, complements PowerServer's secure HIPAA-compliant architecture built upon the Microsoft Azure cloud platform.

06:11 EDT Oracle announces general availability of Oracle Clinical Digital Assistant - Oracle announced general availability of the Oracle Clinical Digital Assistant for ambulatory clinics in the US. The mobile offering combines generative AI, clinical intelligence, multimodal voice and screen driven assistance, and simplified workflows into a single, unified solution that enables providers to give their full attention to the needs of their patients. Integrated with the Oracle Health Electronic Health Record, the solution transforms the doctor-patient experience by combining clinical automation, conversation-based note generation, and proposed clinical follow ups directly at the point of care.

10:10 EDT KPS Capital to sell Eviosys to Sonoco for EUR 3.615B - KPS Capital Partners has entered into an agreement for its portfolio company, Eviosys, to be sold to Sonoco Products (SON), for EUR 3.615B or approximately $3.9B. Sonoco has the option, under certain circumstances, to pay up to $200M of the purchase consideration in the form of Sonoco stock. The transaction is expected to close by the end of 2024, and is subject to completion of required works council consultations and the receipt of required regulatory approvals and other customary closing conditions. Eviosys is a global supplier of metal packaging, producing food cans and ends, aerosol cans, metal closures and promotional packaging to preserve the products of hundreds of consumer brands. Eviosys has the largest metal food can manufacturing footprint in the EMEA region, with over 6,300 employees in 44 manufacturing facilities across 17 countries in Europe, the Middle East and Africa. Eviosys is a global leader in sustainability, with a product portfolio comprised entirely of infinitely recyclable metal packaging and industry-leading performance across a broad spectrum of sustainability metrics. KPS created Eviosys to acquire Crown Holdings' (CCK) EMEA Food and Consumer Packaging Business in August 2021 in a global corporate carve-out transaction. Crown retained a 20% ownership interest in Eviosys. KPS assembled a management team, led by CEO Tomas Lopez, to lead the transformation of Eviosys into one of Europe's largest and most profitable packaging companies. In under three years of ownership, KPS, in partnership with management, successfully transformed Eviosys into a fully independent and significantly more profitable company focused on growth, innovation and sustainability. KPS and Eviosys' management team structurally improved the strategic position and competitiveness of Eviosys, resulting in an approximate 50% improvement in profitability in under three years of KPS ownership.

06:06 EDT Oshkosh Defense receives $27.3M order for Medium Equipment Trailers - Oshkosh Defense, an Oshkosh Corporation business, announced that the U.S. Army Contracting Command - Detroit Arsenal placed a $27.3M order for 57 Medium Equipment Trailers. Oshkosh will execute the order with partner Broshuis B.V. Oshkosh was awarded the five-year Indefinite Delivery/Indefinite Quantity MET production contract in November 2023.

06:04 EDT Fractyl Health to accelerate its REMAIN-1 clinical study - Fractyl Health announced that it will accelerate its REMAIN-1 clinical study, which is evaluating Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 therapy. The Company also announced that the U.S. FDA has approved an amendment to the protocol for the REVITALIZE-1 study of its Revita device, which expands eligibility to patients with T2D who are inadequately controlled on any glucose lowering agent, including GLP-1 agonists and/or insulin, thus expanding the potential U.S. treatment population by nearly six-fold. Fractyl now anticipates reporting open label data from the REVEAL-1 cohort of REMAIN-1 starting in Q4 2024, a mid-point data analysis from REMAIN-1 in Q2 2025, and topline data from REVITALIZE-1 in mid-2025.

10:03 EDT Target, Shopify partner to expand Target Plus assortment - Target Corporation (TGT) announced a partnership with Shopify (SHOP) to offer a selection of its popular merchants and their products on Target Plus, the retailer's third-party, highly curated digital marketplace. The new partnership with Shopify will expand Target Plus through a hand-selected assortment of new and on-trend products and brands like True Classic, Caden Lane and more, giving consumers even more options to explore at affordable prices and with exceptional quality. Target also will be the first mass retailer to work with Shopify to bring select merchants' products into its physical stores in the months to come, offering shoppers even more new brands to discover. Shopify merchants in the U.S. can apply to sell online on Target Plus through Marketplace Connect - an app enabling merchants to seamlessly sell and manage orders on leading marketplaces like Target Plus.

06:02 EDT Ideaya Biosciences announces clinical program updates for IDE397 - IDEAYA Biosciences announced clinical program updates for IDE397, a potential first-in-class Phase 2 MAT2A inhibitor targeting MTAP-deletion solid tumors. The Company is now targeting an IDE397 clinical data update for the IDE397 Phase 2 monotherapy expansion dose in MTAP-deletion bladder and lung cancer in over approximately 15 evaluable patients in the second half of 2024. The clinical data update is anticipated to include a clinical efficacy summary, including a RECIST 1.1 clinical efficacy waterfall, swim-lane plot, and ctDNA molecular response analysis. In addition, at this update the Company also anticipates providing an adverse event, pharmacokinetics and pharmacodynamics summary at the IDE397 Phase 2 monotherapy expansion dose. Next, the Company is initiating an IDE397 Phase 2 monotherapy expansion in MTAP-deletion bladder cancer, in addition to the earlier reported Phase 2 expansion in MTAP-deletion squamous lung cancer. The Company has activated over 35 clinical trial sites globally in the U.S., Canada, Europe, and Asia Pacific to enable potential rapid enrollment for the IDE397 Phase 2 monotherapy expansion in MTAP-deletion lung and bladder cancer, and for the IDEAYA sponsored clinical combination/ IDE397 is a potential first-in-class potent and selective small molecule inhibitor targeting methionine adenosyltransferase 2 alpha in patients having solid tumors with methylthioadenosine phosphorylase deletion. There is an ongoing Phase 2 expansion of IDE397 monotherapy in MTAP-deletion solid tumors, and an Amgen-sponsored Phase 1/2 trial of IDE397 and AMG 193 combination in MTAP-Deletion NSCLC for which the companies intend to develop a joint publication strategy in 2024. Next, there is a Phase 1 clinical trial that will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE397 in combination with Trodelvy. IDEAYA is also advancing multiple preclinical stage MTAP-deletion programs to enable wholly-owned combinations with IDE397, including a program targeting a Development Candidate nomination in the second half of 2024.

05:59 EDT Takeda: Japanese MHLW approves LIVTENCITY - Takeda announced that LIVTENCITY has been approved by the Japanese Ministry of Health, Labour and Welfare for post-transplant cytomegalovirus infection/disease that is refractory to existing anti-CMV therapies. LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.

05:56 EDT MGM Resorts unit to Tipico's U.S. sportsbook - MGM Resorts International announced that its subsidiary, LeoVegas Group, has entered into an agreement to acquire the product and technology platform constituting the U.S sportsbook and online casino from Tipico Group Ltd. This acquisition is the second major investment by LeoVegas, following the acquisition of game developer Push Gaming in 2023. The acquisition will allow LeoVegas to operate a purpose-built proprietary sportsbook across all international markets and brands, with the exception of those exclusive to the BetMGM JV, with a focus on a clean, fast consumer experience with top-class product, pricing and functionality. Tipico will wind down its U.S. operations prior to the closing of the acquisition. As part of the transaction, LeoVegas will acquire certain of Tipico's U.S. facing management, technology and trading teams across the U.S., Colombia and Europe. The transaction is subject to customary closing conditions and is expected to be completed in the third quarter of 2024.

05:34 EDT Sen. Blackburn: 'To Meta, our kids are the product,' calls for passing of KOSA - Tennessee Senator Marsha Blackburn said via X, the platform formerly called Twitter, on Saturday: "One of Meta's executives warned in 2019 of the addictive impacts Instagram and Facebook have on teens. Yet, when he asked CEO Mark Zuckerberg for funding to fix these problems, his request was denied. To Meta, our kids are the product. This is why we need to pass KOSA." Reference Link